| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| ABVC BioPharma Inc. | ABV-1505 | Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2a | Enrollment Conclusion | Oral | Psychiatric |
| AC Immune SA | Crenezumab - (CREAD 2) | Alzheimer’s disease | Phase 3 | Trial Discontinued | Intravenous | Neurology |
| AC Immune SA | Crenezumab - (CREAD 1) | Alzheimer’s disease | Phase 3 | Trial Discontinued | Intravenous | Neurology |
| AC Immune SA | Crenezumab - (API ADAD) | Autosomal Dominant Alzheimer's Disease (ADAD) | Phase 3 | Ongoing | Intravenous | Genetic Disorder |
| AC Immune SA | Crenezumab - (CREAD 2) | Alzheimer’s disease | Phase 3 | Trial Discontinued | Intravenous | Neurology |
| AC Immune SA | Crenezumab - (CREAD 1) | Alzheimer’s disease | Phase 3 | Trial Discontinued | Intravenous | Neurology |
| AC Immune SA | Crenezumab - (API ADAD) | Autosomal Dominant Alzheimer's Disease (ADAD) | Phase 3 | Ongoing | Intravenous | Genetic Disorder |
| AC Immune SA | PI-2620 - (ADvance) | Alzheimer's disease | Phase 3 | Ongoing | Intravenous | Neurology |